Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12896204 | 0.79 | NOTUM (0.70) | NOTUMTSHRTLR8ALDH1A1HPGD | |
| SCHEMBL21729925 | 0.79 | TSHR (0.76) | NOTUML3MBTL1TSHRTLR8KMT2A | |
| SCHEMBL1186047 | 0.77 | NOTUM (1.00) | NOTUMTLR8KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30413235 | 0.77 | NOTUM (0.66) | NOTUML3MBTL1TLR8ALDH1A1HPGD | |
| SCHEMBL21795694 | 0.76 | NOTUM (0.75) | NOTUMTLR8POLBGAAALDH1A1 | |
| SCHEMBL10835887 | 0.74 | NOTUM (0.62) | NOTUMTLR8GAAALDH1A1HPGD | |
| SCHEMBL1347621 | 0.73 | EPHX1 (0.53) | — | |
| SCHEMBL2823140 | 0.73 | NOTUM (0.58) | NOTUML3MBTL1KMT2AKAT6A | |
| SCHEMBL2489203 | 0.72 | KMT2A (0.60) | KMT2APOLBMEN1 | |
| SCHEMBL14482401 | 0.72 | NOTUM (0.55) | NOTUMKMT2APOLBGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | NAT CENTRE FOR BIOLOGICAL SCIENCES TIFR (IN) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | CD4, CD14, CD69 | NOTUM 3172/4885L3MBTL1 2075/4885TSHR 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.